Review article · 2022 · Open access

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen, Yong Peng

Molecular Cancer, 21(1), 99 · Published 11 April 2022 · DOI 10.1186/s12943-021-01434-3

Open PDFView at the publisherCite this paper

In brief

“Proteolysis-targeting chimeras (PROTACs) in cancer therapy” is a 2022 review article by Xinyi Li and 5 co-authors, published in Molecular Cancer. OpenAlex counts 403 citations as of 19 November 2026, which puts it in the top 1% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Molecular Cancer.

Citations
403
Most cited in
2025 (125)
Field-weighted impact
7.59
References
272
Authors
6

Abstract

Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalently-linked ligands recruits target protein and E3 ubiquitin ligase together to trigger proteasomal degradation of target protein by the ubiquitin-proteasome system. PROTAC has emerged as a promising approach for targeted therapy in various diseases, particularly in cancers. In this review, we introduce the principle and development of PROTAC technology, as well as the advantages of PROTACs over traditional anti-cancer therapies. Moreover, we summarize the application of PROTACs in targeting critical oncoproteins, provide the guidelines for the molecular design of PROTACs and discuss the challenges in the targeted degradation by PROTACs.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022). Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Molecular Cancer, 21(1), 99. https://doi.org/10.1186/s12943-021-01434-3

MLA 9

Li, Xinyi, et al. “Proteolysis-targeting chimeras (PROTACs) in cancer therapy.” Molecular Cancer, vol. 21, no. 1, 2022, p. 99. https://doi.org/10.1186/s12943-021-01434-3.

Chicago

Li, Xinyi, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen, and Yong Peng. 2022. “Proteolysis-targeting chimeras (PROTACs) in cancer therapy.” Molecular Cancer 21 (1): 99. https://doi.org/10.1186/s12943-021-01434-3.

Harvard

Li, X. et al. (2022) ‘Proteolysis-targeting chimeras (PROTACs) in cancer therapy’, Molecular Cancer, 21(1), p. 99. doi:10.1186/s12943-021-01434-3.

IEEE

X. Li, W. Pu, Q. Zheng, M. Ai, S. Chen, and Y. Peng, “Proteolysis-targeting chimeras (PROTACs) in cancer therapy,” Molecular Cancer, vol. 21, no. 1, p. 99, 2022, doi: 10.1186/s12943-021-01434-3.

BibTeX

@article{li2022proteolysis,
  title     = {{Proteolysis-targeting chimeras (PROTACs) in cancer therapy}},
  author    = {Li, Xinyi and Pu, Wenchen and Zheng, Qingquan and Ai, Min and Chen, Song and Peng, Yong},
  journal   = {Molecular Cancer},
  year      = {2022},
  volume    = {21},
  number    = {1},
  pages     = {99},
  doi       = {10.1186/s12943-021-01434-3},
  url       = {https://doi.org/10.1186/s12943-021-01434-3}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20222121
20236464
20249696
2025125125
20269797

Its field-weighted citation impact is 7.59: it has been cited 7.59 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • targeted protein degradation
  • E3 ubiquitin ligase
  • ubiquitin-proteasome system
  • proteasomal degradation
  • bifunctional ligands
  • oncoprotein
  • PROTAC design

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022). Proteolysis-targeting chimeras (PROTACs) in cancer therapy. Molecular Cancer, 21(1), 99. https://doi.org/10.1186/s12943-021-01434-3

How many times has this paper been cited?

403 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Molecular Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Xinyi Li, Wenchen Pu, Qingquan Zheng, Min Ai, Song Chen, Yong Peng.

What is the DOI of this paper?

10.1186/s12943-021-01434-3, permanently at https://doi.org/10.1186/s12943-021-01434-3. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.